Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-02 in advanced solid tumors (Phase I/II)
CTR20211884Phase 2Terminated
- Sponsor
- Shanghai Anmai Biotechnology
- Start
- Aug 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emb-02 in Nonhematologic neoplasms, anal squamous cell carcinoma (SCCA), melanoma, cutaneous squamous cell carcinoma (cSCC), non-small cell lung cancer (NSCLC), sponsored by Shanghai Anmai Biotechnology. Started Aug 2021; status: terminated.
02
Drugs
emb-02
03
Conditions
Nonhematologic neoplasmsanal squamous cell carcinoma (SCCA)melanomacutaneous squamous cell carcinoma (cSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211884.